drugset / Trial / NCT03150914
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Phase 3
Active not recruiting
60 enrolled
University of Cincinnati
National Center for Advancing Translational Sciences (NCATS) · collabNational Heart, Lung, and Blood Institute (NHLBI) · collabThe LAM Foundation · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.
Timeline
- Start
- 2018-01-01
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sirolimus | Small molecule | 1 mg | — |